Mode
Text Size
Log in / Sign up

Review of IVIG and bronchoscopic interventions for pediatric EBV-SMT in immunodeficiencyA rare lung tumor in a boy with immune issues may need IVIG and bronchoscopic procedures

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider pulmonary EBV-SMT in pediatric patients with unexplained nodules and immunodeficiency.

This source is a case report review focusing on a single 10-year-old boy with congenital immunodeficiency and an Epstein–Barr virus-associated smooth muscle tumor of the lung. The setting was not reported. The patient underwent bronchoscopic interventions such as electrosnaring, forceps excision, laser therapy, high-frequency electrocautery, and cryotherapy, combined with intravenous immunoglobulin therapy. No comparator group was included in this narrative.

Pathological findings showed Ki-67 positivity between 5% and 8% and diffuse EBER positivity. CD4+ T-cell counts remained persistently low throughout the case. The review notes that tumor recurrence and progression may occur despite the administered treatments. No adverse events or discontinuations were reported in this single case.

The authors highlight that treatments may not prevent tumor recurrence and progression. Pulmonary EBV-SMT should be considered in pediatric patients with unexplained pulmonary nodules and underlying immunodeficiency. This case illustrates the complexity of managing rare tumors in immunocompromised children. Further research is needed to define optimal management strategies for this condition.

This case report describes a 10-year-old boy with congenital immunodeficiency who developed a rare lung tumor linked to the Epstein–Barr virus. The child received bronchoscopic interventions such as electrosnaring, forceps excision, laser therapy, high-frequency electrocautery, and cryotherapy, along with intravenous immunoglobulin therapy. Tumor cells showed diffuse positivity for Epstein–Barr virus and low Ki-67 levels between 5 and 8 percent. CD4+ T-cell counts remained persistently low throughout the case. No adverse events or discontinuations were reported in this single instance. The main concern is that tumor recurrence and progression may still occur despite these treatments. Because this is a single case report, the findings are limited and cannot be generalized to other patients. Clinicians should consider this rare tumor in pediatric patients with unexplained pulmonary nodules and underlying immunodeficiency. More research is needed to confirm the role of these therapies and to understand long-term outcomes for similar patients.

What this means for you:
This single case report suggests IVIG and bronchoscopic procedures may help a rare lung tumor, but recurrence can still happen.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedMay 2026
View Original Abstract ↓
BackgroundPulmonary Epstein–Barr virus-associated smooth muscle tumor (EBV-SMT) is extremely rare in children with congenital immunodeficiency. This case report describes the clinical details of a pediatric pulmonary EBV-SMT case.Case presentationA 10-year-old boy presented with a three-year history of persistent cough and intermittent fever. Chest computed tomography (CT) revealed multiple nodules in both lungs. Histopathological examination of bronchoscopic excision specimens revealed spindle cell proliferation with a preliminary diagnosis of myofibromatosis, followed by immunohistochemical analysis showing positivity for smooth muscle actin (SMA), Ki-67 (5–8%), and calponin, while in situ hybridization showed diffuse positivity for Epstein–Barr virus-encoded RNA (EBER), confirming the diagnosis of EBV-SMT. Further immunological evaluation revealed suspected underlying immune dysfunction, characterized by persistently low CD4 + T-cell counts. The patient underwent multiple bronchoscopic interventions, including electrosnaring and forceps excision, as well as laser therapy, high-frequency electrocautery, and cryotherapy, to manage the largest pulmonary and intrabronchial lesions. He was also managed with regular intravenous immunoglobulin (IVIG) therapy and close clinical monitoring.ConclusionPulmonary EBV-SMT should be considered in pediatric patients with unexplained pulmonary nodules and underlying immunodeficiency. Early diagnosis is essential, and a combination of local tumor control with surgical or bronchoscopic interventions and immunomodulatory therapy may be necessary. However, these treatments may not prevent tumor recurrence and progression, highlighting the challenges in long-term management.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.